Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusionShuai Xia, Lu Lu|Cell Research|2020Cited by 1.4k
Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variantShuai Xia, Shibo Jiang, Lijue Wang et al.|Cell Research|2022Cited by 40